Our results demonstrate that the HiFiCas9-mediated KRAS targeting system can selectively eliminate tumor cells by targeting KRASG12C and KRASG12D driver mutations, highlighting its therapeutic potential in preclinical models. Here, KRAS is linked to neoplasm.